CDX
FaDu
Tumor indication
Head and Neck
Tumor subtype
Squamous Cell Carcinoma
Description
FaDu (Hypopharyngeal Cancer CDX Model)
The FaDu hypopharyngeal carcinoma line was derived from a squamous cell carcinoma of the pharynx. It is classified within head and neck squamous cell carcinoma (HNSCC). FaDu is widely used in studies of drug response in upper aerodigestive tract cancers. Its reproducibility makes it a cornerstone model for HNSCC research.
Key Features:
- Derived from hypopharyngeal squamous carcinoma.
- Epithelial morphology consistent with HNSCC.
- Tumorigenic in xenograft systems.
- Models upper aerodigestive cancers.
Applications:
FaDu is applied in studies of HNSCC drug response, including chemotherapies and targeted agents. It supports biomarker identification for head and neck cancer treatment. Researchers often use FaDu in radiotherapy sensitivity studies. Its consistency makes it valuable for translational oncology pipelines.
Details
- Tumor indication
- Head and Neck
- Tumor subtype
- Squamous Cell Carcinoma
- Organism
- Human
- Mouse sex
- Female
- Lumin data
- Proteomics, RNA-Seq, WES
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.